Psychopharmacology and Psychological Therapies

78 soru

Soru 41Soru →

An individual with a well-documented history of bipolar I disorder is evaluated in the emergency department for altered mental status. According to family members, the patient has become progressively lethargic, confused, and unsteady on their feet over the past 48 hours. The patient has been taking divalproex sodium for several years with excellent mood control. Two weeks ago, a neurologist initiated topiramate for migraine prophylaxis. On examination, the patient is disoriented to time and place. When asked to hold their arms outstretched with wrists extended, a bilateral, non-rhythmic, flapping tremor is observed. Laboratory studies, including a complete blood count, aspartate aminotransferase, alanine aminotransferase, and total bilirubin, are all strictly within normal limits. Which of the following is the most likely cause of this patient's current presentation?

Cevabı ve açıklamayı göster

Cevap: Accumulation of ammonia due to urea cycle interference

Cevap

The correct answer is the accumulation of ammonia due to urea cycle interference, commonly known as valproate-induced hyperammonemic encephalopathy.
The correct answer identifies the accumulation of ammonia due to interference with the urea cycle. Valproic acid can induce hyperammonemic encephalopathy by inhibiting carbamoyl phosphate synthetase I, the rate-limiting enzyme of the urea cycle. This risk is profoundly increased when topiramate is added. Topiramate acts as a carbonic anhydrase inhibitor, decreasing the availability of bicarbonate, which is an essential substrate for the urea cycle. This synergistic inhibition prevents the liver from clearing ammonia, leading to systemic hyperammonemia. The ammonia crosses the blood-brain barrier, causing metabolic encephalopathy characterized by lethargy, confusion, and the classic physical finding of asterixis. Crucially, this syndrome frequently occurs without any evidence of direct hepatocellular damage, meaning liver function tests (AST, ALT) often remain entirely normal.

Adım Adım Çözüm

1
Analyze the patient's current medication list and recent changes.
The patient is on a chronic regimen of divalproex sodium and recently started topiramate.
Identifying recent medication additions is crucial for recognizing adverse drug interactions in psychiatric and neurologic pharmacotherapy.
2
Evaluate the clinical presentation and physical exam findings.
The patient presents with subacute altered mental status, lethargy, and asterixis (a flapping tremor).
Asterixis is a hallmark sign of a metabolic encephalopathy, specifically indicating the accumulation of toxic metabolic byproducts like ammonia in the brain.
3
Interpret the provided laboratory data.
Hepatic transaminases (AST, ALT) and bilirubin are completely normal.
Normal liver function tests rule out acute liver failure (hepatocellular necrosis) as the cause of the metabolic encephalopathy, narrowing the differential to non-hepatic causes of hyperammonemia.
4
Synthesize the mechanism linking the medications to the clinical presentation.
Valproate inhibits carbamoyl phosphate synthetase I in the urea cycle. Topiramate inhibits carbonic anhydrase, reducing bicarbonate (a necessary substrate for the urea cycle). Together, they cause a synergistic failure of ammonia clearance.
Understanding this specific pharmacological synergy explains the isolated hyperammonemia and resulting encephalopathy despite structurally intact liver tissue.

Anahtar Kavram

Valproate-induced hyperammonemic encephalopathy is a life-threatening complication characterized by altered mental status and asterixis with normal liver enzymes. The risk is significantly increased when valproate is co-administered with topiramate.
Soru 42Soru →

A 24-year-old man with a history of schizophrenia is brought to the emergency department from a residential psychiatric facility due to profound muscle stiffness, confusion, and diaphoresis. His vital signs show a temperature of 39.8°C (103.6°F), blood pressure of 165/100 mmHg, and heart rate of 122/min. Physical examination reveals generalized "lead-pipe" rigidity and coarse tremors. He was recently transitioned to intramuscular fluphenazine decanoate. Laboratory studies reveal a serum creatine kinase level of 5,200 U/L. Arrange the following steps in the most appropriate chronological sequence for the management of this patient's current condition and his subsequent long-term psychiatric care.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence begins with the immediate discontinuation of the offending dopamine antagonist, followed immediately by aggressive supportive care, and then specific pharmacologic antidotes if necessary. After clinical resolution, a two-week washout period is required before cautiously restarting a lower-risk atypical antipsychotic.
The management of Neuroleptic Malignant Syndrome (NMS) follows a strict timeline of immediate, short-term, and long-term interventions. The absolute first step is the discontinuation of the offending agent (fluphenazine). This is followed by intensive supportive care (cooling, hydration) to prevent complications like acute kidney injury from rhabdomyolysis. If the patient does not respond adequately to supportive measures, specific pharmacologic therapies such as bromocriptine (dopamine agonist) or dantrolene (ryanodine receptor antagonist) are administered. Following successful treatment and resolution of symptoms, standard psychiatric guidelines dictate a minimum two-week washout period to allow the syndrome to completely clear and to allow receptor equilibration. Finally, when re-initiating treatment for the underlying schizophrenia, a medication with a lower risk of extrapyramidal symptoms and NMS, such as an atypical antipsychotic (e.g., quetiapine), should be selected and titrated cautiously.

Adım Adım Çözüm

1
Diagnose the acute condition based on the clinical presentation.
The patient has Neuroleptic Malignant Syndrome (NMS), characterized by altered mental status, autonomic instability, hyperthermia, and lead-pipe rigidity in the setting of fluphenazine use.
Accurate diagnosis dictates the specific treatment pathway and urgency of intervention.
2
Determine the acute management algorithm for NMS.
The sequence is to first remove the trigger (stop fluphenazine), second stabilize physiology (IV fluids, cooling blankets), and third use targeted antidotes (bromocriptine or dantrolene) if the patient remains severely symptomatic.
This stepwise approach minimizes toxicity while addressing life-threatening complications like rhabdomyolysis and hyperthermia.
3
Determine the post-recovery psychiatric pharmacotherapy protocol.
After NMS resolves, a mandatory 2-week washout period must be observed before utilizing a lower-risk antipsychotic (e.g., quetiapine, clozapine) to manage the underlying schizophrenia.
NMS has a high recurrence rate if antipsychotics are restarted prematurely or if high-potency agents are reused.

Anahtar Kavram

Algorithm for acute treatment and post-recovery pharmacotherapy of Neuroleptic Malignant Syndrome (NMS).
Tahmini Süre:2m 0s
Soru 43Soru →

A number of patients present with unique adverse effects after initiating pharmacological treatment for major depressive disorder. For each clinical presentation, select the most likely responsible antidepressant.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

Sustained, dose-dependent elevations in blood pressure requiring antihypertensive management.
Significant weight gain and increased appetite in a patient who specifically requested a medication without sexual side effects.
A prolonged, painful erection lasting over four hours requiring emergency urologic intervention.
A new-onset generalized tonic-clonic seizure in a patient with a history of electrolyte abnormalities secondary to frequent purging.

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

Venlafaxine matches with dose-dependent hypertension; Mirtazapine matches with weight gain and preserved sexual function; Trazodone matches with priapism; Bupropion matches with seizures in bulimia.
Each antidepressant agent has unique receptor binding affinities that produce distinct toxicity profiles. Norepinephrine reuptake inhibition (Venlafaxine) raises blood pressure. H1 antagonism combined with alpha-2 antagonism (Mirtazapine) stimulates appetite while sparing sexual function. Alpha-1 antagonism (Trazodone) disrupts penile detumescence, causing priapism. Norepinephrine-dopamine reuptake inhibition (Bupropion) lowers the seizure threshold, making it dangerous in bulimia.

Adım Adım Çözüm

1
Evaluate the clinical presentation of dose-dependent hypertension.
Match with Venlafaxine.
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases vascular tone at higher doses due to noradrenergic effects.
2
Evaluate the clinical presentation of weight gain without sexual dysfunction.
Match with Mirtazapine.
Mirtazapine's strong antihistaminic (H1) action causes increased appetite, while its 5-HT2 and 5-HT3 antagonism prevents the sexual dysfunction typical of SSRIs.
3
Evaluate the clinical presentation of a prolonged, painful erection (priapism).
Match with Trazodone.
Trazodone can induce priapism due to its strong alpha-1 adrenergic receptor antagonism, which alters penile blood flow.
4
Evaluate the clinical presentation of a seizure in a patient with bulimia.
Match with Bupropion.
Bupropion lowers the seizure threshold. This risk is heavily magnified in patients with electrolyte shifts from purging behaviors.

Anahtar Kavram

Adverse effect profiles of atypical and SNRI antidepressants
Tahmini Süre:1m 30s
Soru 44Soru →

A 28-year-old woman comes to the clinic for a routine follow-up. She has a 5-year history of bipolar I disorder. Six months ago, she experienced a severe manic episode, and her psychiatric medication regimen was changed due to inadequate symptom control on lithium therapy. At that time, she was transitioned to a different mood stabilizer, and her mood symptoms have remained well-controlled since. She has no other medical conditions. Her only other medication is a combined oral contraceptive pill (ethinyl estradiol and levonorgestrel), which she has taken consistently at the same time every day for the past 3 years without any missed doses. Today, the patient reports a 6-week history of amenorrhea, breast tenderness, and morning nausea. A urine pregnancy test in the clinic is positive. Which of the following psychiatric medications was most likely initiated six months ago?

Cevabı ve açıklamayı göster

Cevap: Carbamazepine

Cevap

Carbamazepine
The correct answer is Carbamazepine. This patient presents with an unintended pregnancy despite perfect adherence to her combined oral contraceptive pill (OCP), highly suggesting a pharmacokinetic drug interaction. Combined OCPs are primarily metabolized by the hepatic cytochrome P450 system, specifically CYP3A4. Carbamazepine is a mood stabilizer and anticonvulsant that acts as a potent inducer of several CYP450 enzymes, including CYP3A4. Initiation of carbamazepine significantly increases the metabolism and clearance of ethinyl estradiol and levonorgestrel, leading to subtherapeutic systemic hormone levels and subsequent contraceptive failure. Female patients of childbearing age starting carbamazepine must be counseled to use alternative or backup non-hormonal contraceptive methods (e.g., copper IUD, barrier methods).

Adım Adım Çözüm

1
Analyze the patient's clinical presentation and medication history.
The patient has an unintended pregnancy despite perfect adherence to combined oral contraceptives, following the recent initiation of a new mood stabilizer for bipolar I disorder.
Identifying contraceptive failure in a highly adherent patient points toward a pharmacokinetic drug-drug interaction.
2
Determine the required mechanism of the drug interaction.
The new medication must be a strong inducer of hepatic cytochrome P450 enzymes (specifically CYP3A4), which metabolize the estrogen and progestin components of the contraceptive.
Enzyme induction accelerates the clearance of the contraceptive hormones, causing subtherapeutic systemic levels and allowing ovulation to occur.
3
Identify the medication from the options that matches this pharmacokinetic profile.
Carbamazepine is a well-known, potent CYP3A4 inducer used in the treatment of bipolar disorder.
Other options either do not affect CYP3A4, act as inhibitors, or have their own metabolism induced by contraceptives without affecting the contraceptive itself.

Anahtar Kavram

Carbamazepine is a potent inducer of hepatic cytochrome P450 enzymes (particularly CYP3A4). It accelerates the metabolism of combined oral contraceptives, which can lead to subtherapeutic hormone levels and unintended pregnancy.
Tahmini Süre:1m 15s
Soru 45Soru →

Emergency medical services bring a 26-year-old woman to the hospital due to severe agitation and confusion that began abruptly this morning. According to her roommate, the patient has been recovering from an upper respiratory tract infection over the past few days and recently started taking a new over-the-counter syrup for a persistent, dry cough. Her only daily prescription medication is citalopram for major depressive disorder. Upon arrival, the patient appears profoundly restless and disoriented. Vital signs show a temperature of 38.9°C (102.0°F), blood pressure of 162/94 mm Hg, heart rate of 128/min, and respiratory rate of 22/min. Physical examination reveals warm, diaphoretic skin and visibly dilated pupils. She has continuous rhythmic muscle twitching in her lower extremities, brisk patellar reflexes (4+ bilaterally), and sustained ankle clonus. Which of the following active ingredients is most likely present in the cough medication this patient consumed?

Cevabı ve açıklamayı göster

Cevap: Dextromethorphan

Cevap

Dextromethorphan
The patient's presentation of altered mental status, autonomic instability (fever, tachycardia, hypertension, diaphoresis), and neuromuscular hyperactivity (hyperreflexia, sustained ankle clonus) in the context of taking an SSRI (citalopram) is highly characteristic of serotonin syndrome. Dextromethorphan, a widely available over-the-counter antitussive, acts as a weak serotonin reuptake inhibitor in addition to its NMDA receptor antagonism. When combined with other serotonergic agents like SSRIs, MAOIs, or SNRIs, dextromethorphan can precipitate life-threatening serotonin toxicity. Recognizing this dangerous psychiatric drug interaction is critical in acute care settings.

Adım Adım Çözüm

1
Analyze the patient's presenting symptoms and vital signs.
The patient exhibits altered mental status, autonomic hyperactivity (fever, tachycardia, hypertension, diaphoresis), and neuromuscular excitability (hyperreflexia, clonus).
To establish a primary clinical syndrome from the physical exam findings.
2
Correlate the clinical syndrome with the patient's medication history.
The triad of symptoms in a patient taking citalopram (an SSRI) strongly indicates serotonin syndrome.
To identify the underlying pathophysiology causing the acute presentation.
3
Identify the over-the-counter medication that could precipitate this syndrome.
Dextromethorphan has serotonin reuptake inhibition properties and can trigger serotonin syndrome when combined with an SSRI.
To determine the precipitating agent and answer the specific question.

Anahtar Kavram

Serotonin syndrome can be precipitated by combining SSRIs with over-the-counter dextromethorphan due to its serotonergic activity.
Soru 46Soru →

Match each acute medication-induced psychiatric emergency or toxidrome with its most appropriate specific therapeutic intervention.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

A patient being treated for depression develops tachycardia, diaphoresis, hyperreflexia, and spontaneous myoclonus shortly after taking over-the-counter dextromethorphan.
A patient with a history of psychosis presents with profound 'lead-pipe' muscle rigidity, extreme hyperthermia, and a creatine kinase level of 5,500 U/L.
A patient managed for bipolar disorder develops severe ataxia, coarse tremors, altered mental status, and a seizure two days after starting hydrochlorothiazide.
A patient with treatment-resistant depression is brought in after an intentional overdose; ECG reveals a QRS duration of 145 msec alongside dry mucous membranes and mydriasis.
A patient taking a medication for atypical depression experiences a sudden, severe throbbing headache and a blood pressure of 215/120 mm Hg after consuming a large amount of aged cheese.

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

The clinical vignettes describe classic psychopharmacological emergencies. The dextromethorphan-precipitated hyperreflexia matches Serotonin Syndrome, treated with cyproheptadine. The 'lead-pipe' rigidity describes NMS, treated with bromocriptine or dantrolene. Thiazide-induced ataxia and seizures indicate severe lithium toxicity, necessitating hemodialysis. The anticholinergic toxidrome with widened QRS identifies TCA overdose, requiring sodium bicarbonate. Finally, the cheese-induced hypertensive emergency represents an MAOI crisis, treated with phentolamine.
Each patient presentation maps to a specific pathophysiological mechanism caused by psychiatric medication toxicity, requiring targeted antidotal therapy. Serotonin syndrome is mediated by excess 5-HT and responds to the antagonist cyproheptadine. NMS results from central dopamine blockade, responding to dopamine agonists. Severe lithium toxicity with neurologic collapse requires rapid removal via hemodialysis. TCA-induced cardiotoxicity relies on sodium channel blockade, which is overcome by the alkaline sodium load of sodium bicarbonate. MAOI tyramine crisis causes excessive alpha-adrenergic stimulation, which is blocked by phentolamine.

Adım Adım Çözüm

1
Analyze the first scenario featuring hyperreflexia and myoclonus following dextromethorphan use.
Diagnosis is Serotonin Syndrome. Dextromethorphan has serotonergic activity and can trigger this syndrome when combined with antidepressants.
Identifying the specific neuromuscular findings (hyperreflexia, myoclonus) differentiates this from NMS and directs treatment toward a 5-HT2A antagonist.
2
Analyze the second scenario featuring 'lead-pipe' rigidity, hyperthermia, and elevated CK.
Diagnosis is Neuroleptic Malignant Syndrome. The profound rigidity and high CK are hallmarks of D2 receptor blockade toxicity.
Recognizing dopamine blockade as the pathophysiology points toward dopamine agonists (bromocriptine) or muscle relaxants (dantrolene) as the correct intervention.
3
Evaluate the third scenario featuring ataxia, coarse tremors, and seizures triggered by a thiazide diuretic.
Diagnosis is severe lithium toxicity. Thiazides decrease lithium clearance, leading to accumulation. The presence of seizures indicates severe, life-threatening toxicity.
While mild lithium toxicity may be managed with hydration, severe neurological symptoms or levels >4.0 mEq/L mandate urgent hemodialysis.
4
Examine the fourth scenario showing anticholinergic signs (dry mouth, mydriasis) and a widened QRS complex.
Diagnosis is Tricyclic Antidepressant (TCA) overdose. The widened QRS is caused by fast sodium channel blockade in the myocardium.
Sodium bicarbonate increases serum pH and extracellular sodium concentration, effectively overcoming the sodium channel blockade and preventing deadly arrhythmias.
5
Assess the final scenario of sudden severe hypertension and headache after eating aged cheese.
Diagnosis is a tyramine-induced hypertensive crisis in a patient taking an MAOI for atypical depression.
Excess tyramine acts as a sympathomimetic. Alpha-adrenergic blockade with phentolamine is the specific antidote for this life-threatening vasoconstriction.

Anahtar Kavram

Diagnosis and management of life-threatening psychopharmacological toxicities and drug-drug interactions.
Soru 47Soru →

A 34-year-old man is newly diagnosed with severe major depressive disorder without psychotic features. Over the course of 18 months, his symptoms prove to be highly refractory to standard treatments despite confirmed medication adherence. Arrange the following clinical management steps in the most appropriate chronological sequence, reflecting the standard escalating algorithm for treatment-resistant depression.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence begins with initiating an SSRI, followed by optimizing its dose, augmenting with an adjunctive agent, and finally considering electroconvulsive therapy (ECT) for refractory disease.
The algorithm progresses from the least invasive and best-tolerated options to more intensive therapies. It starts with monotherapy, optimizes the current trial to ensure adequate dosing, introduces augmentation strategies to synergize mechanisms of action, and finally reserves highly intensive somatic therapies like ECT for definitive treatment resistance.

Adım Adım Çözüm

1
Identify the starting point for a newly diagnosed patient with major depressive disorder.
Initiating SSRI monotherapy is the standard first-line treatment.
SSRIs have a favorable side-effect profile and are first-line agents for major depressive disorder.
2
Determine the next step for a patient showing partial response to initial therapy.
Titrating the initial agent to the maximum tolerated dose is the next logical step.
Ensuring an adequate dose and duration is necessary before concluding an agent is ineffective.
3
Identify the next strategy when the optimized dose fails to achieve full remission.
Augmentation with an adjunctive agent, such as an atypical antipsychotic, is indicated.
Combining medications with different mechanisms can boost efficacy in treatment-resistant cases.
4
Determine the last resort for severe treatment-resistant depression.
Referral for electroconvulsive therapy (ECT) is the final step in this sequence.
ECT is highly efficacious and indicated when multiple pharmacological interventions have failed.

Anahtar Kavram

The step-wise management of treatment-resistant major depressive disorder involves initiating first-line monotherapy, optimizing the dose, augmenting with adjunctive agents, and utilizing somatic therapies like electroconvulsive therapy (ECT) for highly refractory cases.
Soru 48Soru →

A 34-year-old man presents to a new primary care physician complaining of severe fatigue, sleeping 12 to 14 hours a day, significant weight gain, and an inability to experience pleasure in his usual hobbies for the past two months. He states that his depressive symptoms are significantly impairing his daily functioning and requests a specific prescription for an antidepressant. Upon detailed psychiatric review, he mentions that four years ago, he experienced a one-month period where he abruptly quit his job, maxed out several credit cards to start a speculative business venture, and felt "like a superhuman" despite resting for only an hour each night. He was involuntarily hospitalized during that period due to aggressive behavior but subsequently declined long-term medication. He has no other medical conditions and his physical examination is unremarkable. Which of the following is the most appropriate pharmacological therapy for this patient's current symptoms?

Cevabı ve açıklamayı göster

Cevap: Quetiapine

Cevap

Quetiapine is the most appropriate initial treatment for this patient's acute bipolar depression.
This patient is currently experiencing a major depressive episode but has a clear history of a manic episode (duration of at least one week, decreased need for sleep, grandiosity, reckless financial behavior, and severe impairment requiring hospitalization). Therefore, his correct diagnosis is bipolar I disorder, most recent episode depressed. The first-line pharmacological treatment for acute bipolar depression includes specific second-generation antipsychotics (e.g., quetiapine, lurasidone) or mood stabilizers (e.g., lithium). Quetiapine effectively treats the depressive symptoms without increasing the risk of mood destabilization.

Adım Adım Çözüm

1
Analyze the patient's current symptoms.
The patient is experiencing severe fatigue, hypersomnia, weight gain, and anhedonia lasting two months, meeting criteria for a major depressive episode.
Identifying the current mood state is required to select targeted pharmacotherapy.
2
Evaluate the patient's psychiatric history.
The history reveals a distinct one-month period of grandiosity, decreased need for sleep, reckless behavior, and hospitalization, confirming a past manic episode.
A past manic episode changes the diagnosis from major depressive disorder to bipolar I disorder.
3
Determine the appropriate pharmacological guidelines for the diagnosis.
The diagnosis is bipolar I disorder, currently depressed. Antidepressant monotherapy must be avoided due to the risk of manic switch. First-line treatments include specific second-generation antipsychotics like quetiapine or lurasidone.
Standard of care for bipolar depression specifically requires avoiding typical antidepressants in favor of agents with mood-stabilizing properties.

Anahtar Kavram

Patients with bipolar depression must be treated with specific mood stabilizers or second-generation antipsychotics (e.g., quetiapine, lurasidone) rather than antidepressant monotherapy to avoid precipitating a manic episode.
Soru 49Soru →

A 47-year-old man is evaluated in the emergency department for altered mental status, fever, and severe agitation that started a few hours ago. His wife reports that he had been recovering from a minor ankle sprain sustained over the weekend. His medical history is significant for treatment-resistant major depressive disorder, for which he has been taking tranylcypromine for the past two years. His temperature is 39.4°C (102.9°F), blood pressure is 168/105 mm Hg, and pulse is 128/min. On physical examination, the patient is visibly diaphoretic. Neurological examination reveals spontaneous clonus in the lower extremities and horizontal ocular clonus. He recently started taking a new medication prescribed for his ankle sprain. Which of the following medications was most likely prescribed?

Cevabı ve açıklamayı göster

Cevap: Tramadol

Cevap

Tramadol
The patient's presentation of altered mental status, autonomic hyperactivity (fever, diaphoresis, tachycardia, hypertension), and prominent neuromuscular excitability (spontaneous and ocular clonus) is highly characteristic of serotonin syndrome. This life-threatening toxidrome is most commonly precipitated by the concurrent use of multiple serotonergic medications. The patient is already taking tranylcypromine, an irreversible, nonselective monoamine oxidase inhibitor (MAOI) that strongly inhibits the breakdown of serotonin. Tramadol is an analgesic commonly prescribed for musculoskeletal pain that acts as a weak mu-opioid receptor agonist and also inhibits the reuptake of serotonin and norepinephrine. When combined with an MAOI, the dual mechanism of decreased serotonin metabolism and inhibited serotonin reuptake rapidly leads to toxic synaptic serotonin levels, triggering serotonin syndrome. Therefore, tramadol is strictly contraindicated in patients taking MAOIs.

Adım Adım Çözüm

1
Identify the clinical syndrome based on the physical examination and vital signs.
The combination of altered mental status, autonomic hyperactivity (hyperthermia, tachycardia, hypertension, diaphoresis), and neuromuscular excitability (spontaneous and ocular clonus) strongly indicates serotonin syndrome.
Recognizing the characteristic toxidrome is the critical first step to determining its pharmacological cause.
2
Analyze the patient's baseline medications for potential interactions.
The patient takes tranylcypromine, a nonselective monoamine oxidase inhibitor (MAOI), which significantly increases baseline synaptic serotonin levels by preventing its degradation.
MAOIs are a classic component in severe drug-drug interactions leading to serotonin syndrome.
3
Evaluate the answer choices to identify the medication that would interact with the MAOI to trigger this syndrome.
Among the choices provided for an ankle sprain, only tramadol acts to inhibit serotonin reuptake, making it the precipitating agent.
Understanding the specific mechanisms of action of various analgesics helps isolate the exact cause of the life-threatening adverse reaction.

Anahtar Kavram

Dangerous drug interactions with MAOIs precipitating serotonin syndrome
Tahmini Süre:1m 0s
Soru 50Soru →

A 28-year-old man is brought to the emergency department with altered mental status, severe agitation, and tremors. He recently started taking linezolid for a methicillin-resistant Staphylococcus aureus skin infection while maintaining his usual daily dose of sertraline. Vital signs are temperature 39.8°C (103.6°F), pulse 132/min, respirations 22/min, and blood pressure 165/95 mm Hg. Physical examination reveals marked diaphoresis, mydriasis, hyperreflexia, and spontaneous ankle clonus. Arrange the following management steps in the correct sequential order for this patient, from the immediate initial action to interventions reserved for progressive or severe refractory symptoms.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence for managing serotonin syndrome begins with discontinuing the offending agents, followed by supportive care with fluids and benzodiazepines, then utilizing cyproheptadine for refractory symptoms, and finally reserving intubation and neuromuscular blockade for severe, life-threatening hyperthermia or respiratory failure.
Serotonin syndrome is a potentially life-threatening condition caused by excess serotonergic activity, often triggered by a combination of drugs (e.g., SSRIs and linezolid, which has weak monoamine oxidase inhibitor activity). The management algorithm must be followed sequentially based on severity. The absolute first step is the immediate discontinuation of the offending serotonergic agents. Following this, the mainstay of therapy is supportive care, utilizing intravenous fluids for hydration and benzodiazepines (like lorazepam) to control agitation, reduce muscle hyperactivity, and lower blood pressure and heart rate. If the patient's symptoms are refractory to supportive care and benzodiazepines, the specific 5-HT2A antagonist cyproheptadine should be administered. Finally, in extreme cases complicated by severe hyperthermia (temperature > 41.1°C) or impending respiratory failure, the patient requires intubation, mechanical ventilation, and non-depolarizing neuromuscular blockade (e.g., vecuronium) to paralyze the muscles, thereby stopping the primary source of heat generation.

Adım Adım Çözüm

1
Identify the patient's toxidrome.
The combination of altered mental status, autonomic instability, and neuromuscular hyperactivity (hyperreflexia, clonus) in a patient taking a combination of serotonergic agents (sertraline and linezolid) confirms a diagnosis of serotonin syndrome.
Accurate diagnosis is required to dictate the specific treatment algorithm.
2
Determine the first priority in management.
Discontinuation of all serotonergic agents (item 1).
Removing the causative agents prevents further accumulation of serotonin in the synaptic cleft and is always the initial step.
3
Select the first-line medical intervention.
Supportive care with intravenous fluids and benzodiazepines (item 2).
Benzodiazepines control agitation, reduce muscle contraction, and blunt the hyperadrenergic response, while IV fluids manage volume depletion.
4
Determine the appropriate intervention if first-line medical therapy fails.
Administration of cyproheptadine (item 3).
Cyproheptadine is a serotonin antagonist that is indicated when symptoms do not respond adequately to supportive measures and benzodiazepines.
5
Identify the ultimate step for severe, life-threatening toxicity.
Endotracheal intubation and non-depolarizing neuromuscular blockade (item 4).
This is reserved for severe cases with extreme hyperthermia (> 41.1°C) to prevent severe muscle rigidity from generating excessive heat and causing rhabdomyolysis or death.

Anahtar Kavram

The sequential management of serotonin syndrome prioritizes stopping the offending agents, followed by supportive care with benzodiazepines, cyproheptadine for refractory cases, and paralysis/intubation for critical hyperthermia.
Tahmini Süre:1m 30s
Soru 51Soru →

Match each psychotropic medication used during pregnancy with its most characteristic associated fetal or neonatal adverse effect.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

Lithium
Valproate
Paroxetine
Carbamazepine
Diazepam

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

Lithium causes Ebstein anomaly; Valproate causes neural tube defects; Paroxetine causes cardiac septal defects; Carbamazepine causes craniofacial and fingernail hypoplasia; Diazepam causes floppy infant syndrome.
Psychotropic medications carry distinct risks during pregnancy. The matched pairings reflect the classical teratogenic and neonatal adverse effects associated with these specific agents, which must be carefully weighed against the risks of untreated psychiatric illness.

Adım Adım Çözüm

1
Analyze Lithium's teratogenic profile.
Matches with downward displacement of the tricuspid valve.
Lithium causes Ebstein anomaly.
2
Analyze Valproate's teratogenic profile.
Matches with the sac-like protrusion on the lower back.
Valproate causes neural tube defects due to folate interference.
3
Analyze Paroxetine's teratogenic profile.
Matches with ventricular septal defect.
Paroxetine is an SSRI with known cardiac teratogenicity.
4
Analyze Carbamazepine's teratogenic profile.
Matches with midfacial and fingernail hypoplasia.
Carbamazepine causes fetal carbamazepine syndrome.
5
Analyze Diazepam's neonatal effects.
Matches with hypotonia and lethargy.
Benzodiazepines cause floppy infant syndrome when used near term.

Anahtar Kavram

Teratogenic and neonatal adverse effects of psychotropic medications
Soru 52Soru →

A 24-year-old woman comes to an urgent care clinic reporting a painful skin rash, sore throat, and a low-grade fever that began 48 hours ago. Her medical history is notable for bipolar I disorder. She has been stable on valproate for three years. Five weeks ago, her psychiatrist initiated a cross-taper to a new mood stabilizer due to the patient's concerns regarding ongoing weight gain and hair thinning. She has been taking both medications exactly as prescribed. Her temperature is 38.8°C (101.8°F), pulse is 108/min, and blood pressure is 110/70 mm Hg. Physical examination reveals a diffuse, tender, erythematous, macular rash that easily coalesces into large blisters. Gentle pressure on the skin causes the top layer of the epidermis to detach. There are multiple painful erosions on her buccal mucosa and lips. Which of the following pharmacokinetic interactions most likely contributed to this patient's current condition?

Cevabı ve açıklamayı göster

Cevap: Inhibition of UDP-glucuronosyltransferase by the established mood stabilizer

Cevap

The correct answer is the inhibition of UDP-glucuronosyltransferase by the established mood stabilizer, as valproate significantly reduces the clearance of lamotrigine.
This patient presents with fever, mucosal erosions, and a blistering rash with a positive Nikolsky sign (epidermal detachment with gentle pressure), which is the classic presentation of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). In a patient with bipolar disorder who is being cross-tapered off valproate to a weight-neutral alternative, the newly initiated medication is almost certainly lamotrigine. Lamotrigine is highly efficacious for bipolar maintenance but carries a black box warning for severe, life-threatening rashes. The risk of SJS/TEN is significantly increased when lamotrigine is co-administered with valproate. Valproate is a potent inhibitor of UDP-glucuronosyltransferase (UGT), which is the primary hepatic enzyme responsible for the glucuronidation and elimination of lamotrigine. This pharmacokinetic interaction effectively doubles the half-life and serum concentration of lamotrigine. Consequently, when initiating lamotrigine in a patient already taking valproate, the starting dose must be halved and the titration schedule must be remarkably slower to prevent toxic lamotrigine levels and minimize the risk of SJS/TEN.

Adım Adım Çözüm

1
Diagnose the patient's acute dermatologic presentation.
The patient has a blistering rash with mucosal involvement and a positive Nikolsky sign, indicating Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).
Recognizing this life-threatening drug reaction is the first requirement to identify the inciting pharmacologic event.
2
Identify the new psychotropic medication initiated.
The new medication is most likely lamotrigine.
Lamotrigine is a weight-neutral mood stabilizer commonly used for bipolar disorder that carries a well-known black box warning for SJS/TEN.
3
Analyze the pharmacokinetic interaction between the patient's current medications.
Valproate (the established medication) inhibits UDP-glucuronosyltransferase (UGT), the enzyme responsible for clearing lamotrigine.
To determine why the patient developed toxicity despite taking the medications as prescribed, one must understand how valproate alters lamotrigine metabolism.

Anahtar Kavram

Valproate is a potent inhibitor of UDP-glucuronosyltransferase (UGT). When co-administered with lamotrigine, it roughly doubles lamotrigine's half-life, significantly increasing the risk of life-threatening rashes like Stevens-Johnson syndrome.
Tahmini Süre:1m 30s
Soru 53Soru →

A psychiatric consultation is requested for a 31-year-old male inpatient admitted to the medical intensive care unit. The patient was transferred from an outpatient psychiatric facility after developing severe muscle stiffness, diaphoresis, and altered mental status. He has a history of schizoaffective disorder and was recently prescribed fluphenazine. Current vital signs include a pulse of 115/min, blood pressure of 165/95 mmHg, and a temperature of 39.1°C (102.4°F). Physical examination reveals mutism and profound 'lead-pipe' rigidity. Laboratory evaluation reveals a significantly elevated serum creatine kinase level. The diagnosis of neuroleptic malignant syndrome (NMS) is established.

Arrange the following clinical interventions in the correct chronological sequence for managing this patient's condition, from the most immediate initial step to the final long-term management step.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence for managing neuroleptic malignant syndrome is: 1) Discontinue the offending agent, 2) Initiate aggressive supportive care, 3) Administer targeted pharmacologic therapy for refractory/severe cases, and 4) Observe a minimum two-week washout period prior to antipsychotic rechallenge.
The standard of care for neuroleptic malignant syndrome strictly follows a sequence prioritizing the removal of the inciting agent, followed by physiological rescue via supportive care. Pharmacologic treatments (dopamine agonists like bromocriptine/amantadine, or ryanodine receptor antagonists like dantrolene) are reserved for cases that are severe or unresponsive to supportive measures. Finally, long-term management requires a mandatory waiting period of at least two weeks before any careful re-exposure to dopamine antagonists.

Adım Adım Çözüm

1
Identify the primary cause of the life-threatening condition and remove it.
Discontinuation of fluphenazine.
Continuing the dopamine antagonist will exacerbate the central dopamine blockade driving the syndrome.
2
Stabilize the patient's acute physiological derangements.
Administration of intravenous fluids and cooling measures.
Rhabdomyolysis and severe hyperthermia can rapidly lead to acute renal failure and cardiovascular collapse without immediate supportive care.
3
Provide definitive medical therapy if supportive care is insufficient.
Administration of bromocriptine or dantrolene.
These agents directly counteract the dopamine blockade or muscle rigidity driving the hypermetabolic state in severe cases.
4
Plan for long-term psychiatric management after stabilization.
Two-week washout period before rechallenge.
Reintroducing antipsychotics too quickly carries a high risk of NMS recurrence; a two-week minimum ensures full clearance of the previous agent and physiological reset.

Anahtar Kavram

Stepwise clinical management algorithm for Neuroleptic Malignant Syndrome (NMS).
Tahmini Süre:1m 0s
Soru 54Soru →

Match each patient's clinical presentation to the psychological therapy that represents the most appropriate, evidence-based first-line treatment for their specific condition.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

A 22-year-old woman with a history of recurrent self-mutilation, intense affective instability, chronic feelings of emptiness, and frantic efforts to avoid abandonment.
A 45-year-old man with major depressive disorder triggered by a contentious divorce, currently struggling to adapt to his new role as a single father.
A 30-year-old woman with panic disorder who catastrophically misinterprets normal exercise-induced tachycardia as an impending myocardial infarction.
A 28-year-old man with obsessive-compulsive disorder who experiences intrusive images of a house fire and subsequently spends hours checking the stove.

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

Patient 1 (Borderline Personality Disorder) matches with Dialectical Behavior Therapy. Patient 2 (Depression with Role Transition) matches with Interpersonal Psychotherapy. Patient 3 (Panic Disorder) matches with Cognitive-Behavioral Therapy. Patient 4 (Obsessive-Compulsive Disorder) matches with Exposure and Response Prevention.
Each psychiatric disorder has a preferred, evidence-based psychotherapeutic approach. Borderline personality disorder (affective instability, self-harm) is treated with DBT. Depression tied to major life changes (divorce, role transition) is treated with IPT. Panic disorder (catastrophizing physical symptoms) is treated with CBT. OCD (obsessions and compulsions) is treated with ERP.

Adım Adım Çözüm

1
Diagnose the primary psychiatric condition for each patient based on their clinical vignette.
Patient 1 has Borderline Personality Disorder (BPD). Patient 2 has Major Depressive Disorder (MDD) linked to a significant life event. Patient 3 has Panic Disorder. Patient 4 has Obsessive-Compulsive Disorder (OCD).
Identifying the correct underlying diagnosis is a prerequisite to selecting the specific, evidence-based first-line psychological treatment.
2
Determine the first-line psychotherapy for Borderline Personality Disorder.
Dialectical behavior therapy (DBT) is the primary treatment.
DBT was specifically developed for BPD to reduce self-harm behaviors and improve emotion regulation through mindfulness and distress tolerance skills.
3
Determine the optimal psychotherapy for MDD heavily associated with a recent life change and relationship stress.
Interpersonal psychotherapy (IPT) is specifically indicated.
IPT is an evidence-based treatment for depression that focuses on role transitions, interpersonal disputes, and grief, making it ideal for this presentation.
4
Determine the optimal psychotherapy for Panic Disorder characterized by somatic misinterpretations.
Cognitive-behavioral therapy (CBT) is first-line.
CBT helps patients with panic disorder identify and systematically challenge their catastrophic misinterpretations of normal bodily sensations.
5
Determine the gold-standard psychotherapy for Obsessive-Compulsive Disorder.
Exposure and response prevention (ERP) is the specific modality required.
ERP breaks the cycle of OCD by deliberately exposing the patient to the anxiety-provoking obsession while strictly preventing the compensatory compulsion.

Anahtar Kavram

Selection of specific, evidence-based psychological therapies tailored to distinct psychiatric diagnoses and clinical presentations.
Soru 55Soru →

A 38-year-old man is brought to the emergency department by his husband due to a sudden, severe, pounding headache, blurred vision, and chest palpitations. The symptoms began approximately 45 minutes ago. The patient has a history of severe, treatment-resistant major depressive disorder. He recently started a new psychiatric medication after trials of several selective serotonin reuptake inhibitors and a serotonin-norepinephrine reuptake inhibitor failed to improve his mood. Earlier this evening, he attended a holiday party where he consumed multiple glasses of tap beer, aged cheddar cheese, and cured sausages. His temperature is 37.2°C (99.0°F), blood pressure is 218/124 mm Hg, pulse is 122/min, and respirations are 18/min. Physical examination reveals a diaphoretic and tremulous man. Neurological examination shows no focal deficits, and an unenhanced head CT scan reveals no abnormalities. Which of the following medications is this patient most likely taking?

Cevabı ve açıklamayı göster

Cevap: Tranylcypromine

Cevap

Tranylcypromine
The correct answer is tranylcypromine, which is a nonselective monoamine oxidase inhibitor (MAOI). MAOIs (such as tranylcypromine, phenelzine, and isocarboxazid) are highly effective but are typically reserved for treatment-resistant major depressive disorder or atypical depression due to their severe side effect profile and dietary restrictions. Monoamine oxidase-A (MAO-A) in the gastrointestinal tract and liver is responsible for breaking down dietary tyramine, a naturally occurring sympathomimetic amine found in aged cheeses, cured and smoked meats, fermented products, and tap beer. When a patient taking an MAOI consumes these tyramine-rich foods, the un-metabolized tyramine enters the systemic circulation and is taken up by sympathetic nerve terminals. Once inside, it displaces massive amounts of stored norepinephrine from presynaptic vesicles into the synaptic cleft. This sudden surge of catecholamines causes severe alpha-1 adrenergic receptor stimulation, resulting in widespread vasoconstriction and an acute hypertensive crisis. Patients classically present with a sudden severe headache, blurred vision, palpitations, diaphoresis, and dangerously elevated blood pressure. Immediate treatment with an alpha-adrenergic antagonist, such as phentolamine, is often required.

Adım Adım Çözüm

1
Evaluate the patient's acute clinical presentation and vital signs.
The patient presents with a severe headache, palpitations, diaphoresis, and severe hypertension (blood pressure 218/124 mm Hg).
Identifying a hypertensive emergency with target organ symptoms (headache, blurred vision) is the first step in determining the underlying etiology.
2
Analyze the patient's psychiatric history and activities prior to symptom onset.
The patient recently started a new medication for treatment-resistant depression and consumed tap beer, aged cheese, and cured meats just before the onset of symptoms.
Connecting the dietary intake of tyramine-rich foods to the onset of the hypertensive crisis narrows the differential diagnosis to a specific drug-diet interaction.
3
Identify the psychiatric medication class associated with this specific dietary interaction.
Monoamine oxidase inhibitors (MAOIs) prevent the gastrointestinal breakdown of dietary tyramine, leading to a profound sympathetic surge.
Tyramine is a sympathomimetic amine that displaces norepinephrine from presynaptic vesicles when its metabolism by MAO-A is inhibited.
4
Select the MAOI from the given pharmacological options.
Tranylcypromine is the only MAOI listed among the options.
Recognizing the specific generic names of MAOIs is required to determine the correct medication causing this patient's crisis.

Anahtar Kavram

MAOI-induced hypertensive crisis triggered by tyramine-rich foods
Soru 56Soru →

A 34-year-old man with treatment-resistant schizophrenia is brought to the emergency department by his partner after experiencing a generalized tonic-clonic seizure lasting approximately 2 minutes. He has no prior history of seizures. His psychotic symptoms have been well controlled on a stable regimen of clozapine 400 mg daily for the past 3 years. Four weeks ago, the patient suffered an uncomplicated myocardial infarction and was discharged on aspirin and atorvastatin. At that time, the patient successfully quit smoking cold turkey after previously smoking 2 packs of cigarettes daily for 15 years. He reports no illicit drug or alcohol use. His temperature is 37.1°C (98.8°F), blood pressure is 118/76 mm Hg, pulse is 88/min, and respirations are 16/min. Physical examination reveals a postictal state but is otherwise unremarkable. Laboratory studies show an absolute neutrophil count of 5,200/mm35,200/mm^3 and normal liver function tests. Which of the following is the most likely mechanism responsible for this patient's new-onset seizure?

Cevabı ve açıklamayı göster

Cevap: Decreased induction of a hepatic cytochrome P450 enzyme

Cevap

Decreased induction of a hepatic cytochrome P450 enzyme
The correct answer identifies the loss of cytochrome P450 enzyme induction as the cause of the seizure. Polycyclic aromatic hydrocarbons present in tobacco smoke are potent inducers of CYP1A2, the primary hepatic enzyme responsible for metabolizing clozapine. When a patient who is stabilized on clozapine abruptly stops smoking, the induction of CYP1A2 is lost. This leads to a rapid decrease in clozapine clearance and a subsequent elevation in serum clozapine levels. Clozapine is well known to lower the seizure threshold in a dose-dependent manner. The sudden, drastic increase in clozapine concentration precipitated this patient's new-onset generalized tonic-clonic seizure.

Adım Adım Çözüm

1
Identify the patient's baseline medications and recent lifestyle changes.
The patient is on a high but stable dose of clozapine and recently underwent abrupt smoking cessation following a myocardial infarction.
Clozapine relies heavily on specific metabolic pathways that are influenced by environmental factors.
2
Determine the metabolic interaction between tobacco smoke and clozapine.
Polycyclic aromatic hydrocarbons in tobacco smoke are potent inducers of the hepatic enzyme cytochrome P450 1A2 (CYP1A2), which is the primary enzyme responsible for clozapine metabolism.
Understanding the enzyme system involved explains how the patient's medication levels are altered.
3
Analyze the physiological effect of smoking cessation on clozapine levels.
Abrupt smoking cessation removes the CYP1A2 induction, causing a relative decrease in enzyme activity. This leads to reduced clozapine clearance and a significant rise in serum clozapine levels.
This establishes the mechanism for medication toxicity.
4
Correlate the elevated clozapine levels with the clinical presentation.
Clozapine has a known, dose-dependent risk of causing seizures. The abrupt rise in serum clozapine resulting from the loss of CYP1A2 induction precipitated the tonic-clonic seizure.
This confirms that the physiological change directly caused the patient's symptom.

Anahtar Kavram

Polycyclic aromatic hydrocarbons in tobacco smoke strongly induce cytochrome P450 1A2 (CYP1A2). Abrupt smoking cessation in a patient on clozapine (a CYP1A2 substrate) removes this induction, leading to elevated clozapine levels and an increased risk of dose-dependent toxicities, such as seizures.
Tahmini Süre:1m 30s
Soru 57Soru →

A 24-year-old man is diagnosed with schizophrenia after presenting with a 7-month history of auditory hallucinations and persecutory delusions. His psychiatrist is planning a long-term pharmacotherapy strategy. Assuming the patient exhibits an inadequate clinical response to each consecutive intervention despite optimal dosing and confirmed medication adherence, arrange the following treatment steps in the correct standard algorithm for the management of schizophrenia.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence begins with a first-line antipsychotic, followed by an alternative first-line agent, then clozapine for treatment resistance, and finally clozapine augmentation.
The standard treatment algorithm for schizophrenia dictates that patients begin with a first-line antipsychotic. If the first trial fails due to lack of efficacy or intolerability, a different first-line antipsychotic should be tried. Only after two adequate trials of different antipsychotics fail is a patient diagnosed with treatment-resistant schizophrenia, for which clozapine is the gold standard. If clozapine monotherapy is insufficient, augmentation with ECT or another agent is the final step.

Adım Adım Çözüm

1
Identify the first step in pharmacological management for a newly diagnosed patient with schizophrenia.
Initiate a trial of a first-line second-generation antipsychotic (e.g., risperidone).
Second-generation antipsychotics are the preferred initial treatment due to a lower risk of extrapyramidal symptoms compared to first-generation agents.
2
Determine the next management step following a single failed adequate medication trial.
Switch to a trial of an alternative first-line antipsychotic (e.g., aripiprazole).
Treatment-resistant schizophrenia requires the failure of at least two antipsychotics. Therefore, a second trial with a different standard agent is indicated before moving to clozapine.
3
Identify the threshold and treatment for treatment-resistant schizophrenia.
Initiate a trial of clozapine with absolute neutrophil count (ANC) monitoring.
After failing two adequate trials of different antipsychotics, the patient is considered treatment-resistant. Clozapine is the only evidence-based medication for this stage.
4
Determine the strategy for a patient who has an inadequate response to optimized clozapine monotherapy.
Augment clozapine with an additional agent (e.g., electroconvulsive therapy or a second antipsychotic).
If clozapine monotherapy fails, augmentation strategies such as adding a second antipsychotic, a mood stabilizer, or electroconvulsive therapy (ECT) are employed.

Anahtar Kavram

The pharmacological treatment algorithm for schizophrenia progresses from a first-line antipsychotic to an alternative first-line antipsychotic, followed by clozapine (after two failed trials), and finally clozapine augmentation.
Tahmini Süre:1m 30s
Soru 58Soru →

A 62-year-old man is evaluated in the hospital due to rapidly worsening mental status. He was admitted three days ago for complicated cellulitis of the right lower extremity and was started on intravenous linezolid. His past medical history is significant for major depressive disorder, for which he has taken fluoxetine for several years. Today, he developed sudden-onset severe agitation, restlessness, and confusion. His temperature is 39.2°C (102.6°F), blood pressure is 165/100 mmHg, pulse is 124/min, and respirations are 22/min. Physical examination demonstrates excessive diaphoresis and shivering. Neurological examination reveals prominent hyperreflexia and inducible ankle clonus bilaterally in the lower extremities. Initial management with intravenous normal saline, cooling blankets, and intravenous lorazepam does not sufficiently control his severe symptoms. Which of the following is the most appropriate next step in pharmacologic management?

Cevabı ve açıklamayı göster

Cevap: Administer cyproheptadine

Cevap

The most appropriate next step is to administer cyproheptadine.
This patient is experiencing serotonin syndrome, a potentially life-threatening condition caused by excessive serotonergic neurotransmission. It is classically precipitated by the combination of a selective serotonin reuptake inhibitor (SSRI), such as fluoxetine, and a monoamine oxidase inhibitor (MAOI). Linezolid is an antibiotic that also possesses reversible nonselective MAOI activity, making it a dangerous precipitant when combined with other serotonergic agents. The clinical triad includes altered mental status, autonomic hyperactivity (fever, tachycardia, diaphoresis), and neuromuscular abnormalities (hyperreflexia, clonus). Initial management consists of discontinuing the offending agents, providing supportive care (IV fluids, cooling), and administering benzodiazepines (e.g., lorazepam) for agitation and tremor. When supportive measures and benzodiazepines fail to control severe symptoms, cyproheptadine—a 5-HT1A and 5-HT2A receptor antagonist—is the appropriate pharmacological treatment.

Adım Adım Çözüm

1
Analyze the patient's medication list for dangerous interactions.
The patient is taking fluoxetine (a selective serotonin reuptake inhibitor) and linezolid (an antibiotic with reversible, nonselective monoamine oxidase inhibitor activity).
Identifying concurrent medications is necessary to determine the underlying pathophysiology of the acute clinical deterioration.
2
Correlate the physical examination findings with the medication interaction.
The triad of altered mental status, autonomic hyperactivity (fever, tachycardia, diaphoresis), and neuromuscular abnormalities (hyperreflexia, clonus) points strictly to Serotonin Syndrome.
Differentiating serotonin syndrome from other toxidromes (like NMS or anticholinergic toxicity) dictates the correct antidote.
3
Determine the appropriate sequential management based on symptom severity.
Because the patient's symptoms are severe and refractory to initial supportive measures and benzodiazepines (lorazepam), administration of cyproheptadine is indicated.
Cyproheptadine is a specific 5-HT2A receptor antagonist that directly counteracts the excessive serotonergic tone causing the syndrome.

Anahtar Kavram

Serotonin syndrome is a potentially life-threatening condition caused by excess serotonergic activity, often triggered by combining SSRIs with MAOIs (including linezolid). It is managed initially with supportive care and benzodiazepines, followed by cyproheptadine for refractory or severe cases.
Soru 59Soru →

A 31-year-old man presents to the clinic to discuss starting medication for newly diagnosed major depressive disorder. He is prescribed escitalopram 10 mg daily. The physician provides psychoeducation regarding what to expect during the course of treatment. Arrange the following clinical events in the most likely chronological sequence of their typical onset or occurrence after initiating this selective serotonin reuptake inhibitor (SSRI).

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct chronological sequence is: 1) Emergence of serotonergic side effects, 2) Improvement in neurovegetative symptoms, 3) Significant relief of core affective symptoms, and 4) Attainment of peak therapeutic response.
The chronological timeline of selective serotonin reuptake inhibitor (SSRI) treatment follows a predictable pattern dictated by acute synaptic changes followed by delayed neuroadaptations. Immediate blockade of the serotonin transporter causes an acute increase in synaptic serotonin, leading to early onset side effects such as nausea (due to 5-HT3 receptors in the gut) and jitteriness. Therapeutic effects are delayed. Neurovegetative symptoms (energy, sleep, appetite) improve first, typically within 1 to 2 weeks. Core affective symptoms (depressed mood, anhedonia, hopelessness) require downstream neuroplastic changes, such as the downregulation of presynaptic 5-HT1A autoreceptors, which takes 4 to 6 weeks. Finally, reaching the absolute peak therapeutic benefit of a given dose requires a full clinical trial of 8 to 12 weeks before assessing whether remission has been achieved.

Adım Adım Çözüm

1
Identify the timeline of immediate adverse effects.
Side effects like nausea and jitteriness occur within hours to days.
These are direct, acute physiological responses to increased synaptic serotonin before receptor downregulation occurs.
2
Determine the first domain of therapeutic improvement.
Neurovegetative symptoms (energy, sleep) improve within 1-2 weeks.
These physiological symptoms of depression respond faster than cognitive and affective symptoms.
3
Identify the timeline for core mood improvement.
Depressed mood and anhedonia typically improve after 4-6 weeks.
This delay is mediated by complex neuroplastic changes, including receptor downregulation and increased brain-derived neurotrophic factor (BDNF) expression.
4
Determine the duration required for a full therapeutic trial.
Peak therapeutic response at a specific dose is reached at 8-12 weeks.
This is the timeline required to definitively assess whether a patient has achieved remission or requires a dose increase or medication switch.

Anahtar Kavram

Timeline of selective serotonin reuptake inhibitor (SSRI) therapeutic effects and adverse events
Soru 60Soru →

A 32-year-old woman with a history of bipolar I disorder comes to the outpatient psychiatry clinic due to a 4-week history of depressed mood, profound fatigue, and sleeping up to 14 hours a day. Her last manic episode occurred two years ago, and she has been maintained on a stable dose of valproate since that time. Vital signs include a heart rate of 72/min, blood pressure of 118/76 mm Hg, and respiratory rate of 14/min. Mental status examination reveals psychomotor retardation, a blunted affect, and a sad mood. She denies any suicidal ideation. The physician decides to add lamotrigine to her current regimen to target the depressive symptoms. To minimize the risk of a life-threatening dermatologic complication, which of the following pharmacokinetic principles must be applied to the management of this patient?

Cevabı ve açıklamayı göster

Cevap: Valproate inhibits the glucuronidation of lamotrigine, requiring a lower starting dose of lamotrigine.

Cevap

Valproate inhibits the glucuronidation of lamotrigine, requiring a lower starting dose of lamotrigine.
The correct principle is that valproate inhibits the hepatic glucuronidation of lamotrigine. Lamotrigine is primarily metabolized in the liver by uridine 5'-diphospho-glucuronosyltransferase (UGT). Valproate is a strong inhibitor of UGT. When lamotrigine is added to a regimen containing valproate, its clearance is significantly decreased, and its elimination half-life is nearly doubled. Because rapid escalation of lamotrigine serum levels is the most significant risk factor for developing Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), the starting dose of lamotrigine must be reduced (usually by 50%, e.g., to 25 mg every other day) and titrated much more slowly in patients taking valproate.

Adım Adım Çözüm

1
Identify the primary clinical objective and the current medication regimen.
The goal is to initiate lamotrigine for breakthrough bipolar depression in a patient currently taking valproate.
Establishing the medication combination is essential for identifying potential drug-drug interactions.
2
Recall the metabolic pathways and interaction profiles of the specific psychotropic agents.
Valproate is a broad inhibitor of hepatic enzymes, most notably uridine 5'-diphospho-glucuronosyltransferase (UGT), which is the exact enzyme responsible for clearing lamotrigine.
Understanding the pharmacokinetics dictates how the new medication should be prescribed.
3
Determine the clinical consequence of the interaction.
Inhibition of UGT by valproate nearly doubles the elimination half-life of lamotrigine. Rapid escalation of lamotrigine levels is the primary risk factor for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
The question specifically asks how to avoid a life-threatening dermatologic complication (SJS).
4
Select the appropriate clinical management principle.
The starting dose and titration schedule of lamotrigine must be significantly reduced (typically by 50%) when added to valproate.
This directly answers the prompt's question regarding the necessary pharmacokinetic adjustments.

Anahtar Kavram

Valproate inhibits hepatic glucuronidation (UGT), doubling the half-life of lamotrigine. To prevent Stevens-Johnson syndrome, lamotrigine must be initiated at a reduced dose when prescribed with valproate.
Tahmini Süre:1m 15s
ÖncekiSayfa 3 / 4Sonraki
Psychopharmacology and Psychological Therapies Alıştırma Soruları — USMLE Step 2 CK — Sayfa 3 | Examkin